Viridian Therapeutics (VRDN)
NASDAQ:VRDN
Want to see VRDN full AI Analyst Report?
Total Valuation
Viridian Therapeutics has a market cap or net worth of $1.78B. The enterprise value is $1.43B.
Market Cap$1.78B
Enterprise Value$1.43B
Share Statistics
Viridian Therapeutics has 103,074,740 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding103,074,740
Owned by Insiders4.99%
Owned by Institutions44.06%
Financial Efficiency
Viridian Therapeutics’s return on equity (ROE) is -0.47 and return on invested capital (ROIC) is -43.81%.
Return on Equity (ROE)-0.47
Return on Assets (ROA)-0.38
Return on Invested Capital (ROIC)-43.81%
Return on Capital Employed (ROCE)-0.44
Revenue Per Employee495.45K
Profits Per Employee-2.40M
Employee Count143
Asset Turnover0.08
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Viridian Therapeutics is ―. Viridian Therapeutics’s PEG ratio is 0.46.
PE Ratio―
PS Ratio37.25
PB Ratio3.65
Price to Fair Value3.65
Price to FCF-9.53
Price to Operating Cash Flow-5.81
PEG Ratio0.46
Income Statement
In the last 12 months, Viridian Therapeutics had revenue of 70.85M and earned -342.60M in profits. Earnings per share was -3.32.
Revenue70.85M
Gross Profit70.85M
Operating Income-363.39M
Pretax Income-342.60M
Net Income-342.60M
EBITDA-337.19M
Earnings Per Share (EPS)-3.32
Cash Flow
In the last 12 months, operating cash flow was -303.39M and capital expenditures -432.00K, giving a free cash flow of -303.82M billion.
Operating Cash Flow-303.39M
Free Cash Flow-303.82M
Free Cash Flow per Share-2.95
Dividends & Yields
Viridian Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.97
52-Week Price Change27.04%
50-Day Moving Average18.46
200-Day Moving Average24.31
Relative Strength Index (RSI)51.85
Average Volume (3m)814.59K
Important Dates
Viridian Therapeutics upcoming earnings date is Aug 12, 2026, TBA (Confirmed).
Last Earnings DateMay 5, 2026
Next Earnings DateAug 12, 2026
Ex-Dividend Date―
Financial Position
Viridian Therapeutics as a current ratio of 12.65, with Debt / Equity ratio of 8.05%
Current Ratio12.65
Quick Ratio12.65
Debt to Market Cap0.02
Net Debt to EBITDA0.48
Interest Coverage Ratio-73.44
Taxes
In the past 12 months, Viridian Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Viridian Therapeutics EV to EBITDA ratio is -7.35, with an EV/FCF ratio of -8.95.
EV to Sales34.97
EV to EBITDA-7.35
EV to Free Cash Flow-8.95
EV to Operating Cash Flow-8.96
Balance Sheet
Viridian Therapeutics has $762.18M in cash and marketable securities with $51.17M in debt, giving a net cash position of $711.01M billion.
Cash & Marketable Securities$762.18M
Total Debt$51.17M
Net Cash$711.01M
Net Cash Per Share$6.90
Tangible Book Value Per Share$8.52
Margins
Gross margin is 99.38%, with operating margin of -512.91%, and net profit margin of -483.57%.
Gross Margin99.38%
Operating Margin-512.91%
Pretax Margin-483.57%
Net Profit Margin-483.57%
EBITDA Margin-475.93%
EBIT Margin-476.58%
Analyst Forecast
The average price target for Viridian Therapeutics is $32.08, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$32.08
Price Target Upside116.78% Upside
Analyst ConsensusStrong Buy
Analyst Count14
Revenue Growth Forecast23382.78%
EPS Growth Forecast7.01%